BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9045345)

  • 1. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel.
    Calvert AH
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-85-S2-90. PubMed ID: 9045345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.
    Calvert AH; Boddy A; Bailey NP; Siddiqui N; Humphreys A; Hughes A; Robson L; Gumbrell L; Thomas H; Chapman F
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):91-8; discussion 99-100. PubMed ID: 7481870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy.
    Kearns CM; Egorin MJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-91-S2-96. PubMed ID: 9045346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of paclitaxel and carboplatin in combination.
    Kearns CM; Belani CP; Erkmen K; Zuhowski M; Hiponia D; Zacharski D; Engstrom C; Ramanathan R; Trenn MR; Aisner J
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):1-4; discussion 5-7. PubMed ID: 7481850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene.
    Calvert AH; Ghokul S; Al-Azraqi A; Wright J; Lind M; Bailey N; Highley M; Siddiqui N; Lunec J; Sinha D; Boddy A; Roberts T; Fenwick J
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):90-4. PubMed ID: 10190788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.
    ten Bokkel Huinink W; Veenhof C; Huizing M; Rodenhuis S; Helmerhorst T; Dubbelman R; Dalesio O; Beijnen J; Winograd B
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-31-S2-33. PubMed ID: 9045333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacology of platinum analogs-taxanes interactions].
    Boisdron-Celle M; Gamelin E
    Bull Cancer; 2000 Aug; 87 Spec No():30-3. PubMed ID: 11082720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of carboplatin administered in combination with paclitaxel.
    van Warmerdam LJ; Huizing MT; Giaccone G; Postmus PE; ten Bokkel Huinink WW; van Zandwijk N; Koolen MG; Helmerhorst TJ; van der Vijgh WJ; Veenhof CH; Beijnen JH
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-97-S2-104. PubMed ID: 9045347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
    Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Calvert H; Boddy AV; Hollema H; Féty R; Van der Vijgh WJ; Hempel G; Chatelut E; Karlsson M; Wilkins J; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH
    Clin Cancer Res; 2007 Nov; 13(21):6410-8. PubMed ID: 17975154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel.
    Obasaju CK; Johnson SW; Rogatko A; Kilpatrick D; Brennan JM; Hamilton TC; Ozols RF; O'Dwyer PJ; Gallo JM
    Clin Cancer Res; 1996 Mar; 2(3):549-52. PubMed ID: 9816202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer.
    Birch R; Weaver CH; Hainsworth JD; Bobo C; Greco FA
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-135-S12-137. PubMed ID: 9331138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer.
    Roychowdhury DF; Desai P; Zhu YW
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-37-S12-40. PubMed ID: 9331119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel in salvage therapy for germ cell tumors.
    Motzer RJ
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.